1. Introduction {#sec1-marinedrugs-18-00383}
===============

Since 1950, the nucleoside spongothymidine, which is obtained from the Caribbean sponge *Cryptotethia* \[[@B1-marinedrugs-18-00383]\], and the derivative of this nucleoside 1-β-D-arabinofuranosylcytosine (Ara-C) have been approved as the first marine-origin clinical medications used in treatment of leukemia in 1969. Marine natural products (MNPs) from marine invertebrates, such as Porifera and Cnidaria, played important roles in drug discovery due to their complex structures and interesting bioactivities \[[@B2-marinedrugs-18-00383],[@B3-marinedrugs-18-00383]\]. Most of the pharmaceutical coral reef organisms are claimed to be endangered species. In order to protect natural populations and habitats of these marine organisms from overexploitation and to support bioactive materials for further study and medicinal use \[[@B4-marinedrugs-18-00383]\], a cultured octocoral *Briareum stechei* (Kükenthal, 1908), which was previously identified as *Briareum excavatum* (Nutting, 1911) \[[@B5-marinedrugs-18-00383]\], was studied for its interesting chemical constituents related to briarane-type diterpenoids. Herein, we report on the isolation, structure determination, and anti-inflammatory activity of four unreported isolates, briarenols Q--T (**1**--**4**) ([Figure 1](#marinedrugs-18-00383-f001){ref-type="fig"}).

2. Results and Discussion {#sec2-marinedrugs-18-00383}
=========================

The octocoral *B. stechei* was harvested in an 80 ton culturing tank in April 2016. This target organism was freeze-dried and ground, followed by exhaustive extraction in a mixture of dichloromethane (CH~2~Cl~2~) and methanol (MeOH). Normal- and reverse-phase HPLC yielded four new briarane diterpenoids, briarenols Q--T (**1**--**4**).

Briarenol Q (**1**), $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +22 (*c* 0.1, CHCl~3~), was obtained as an amorphous powder with the molecular formula C~27~H~34~O~12~, based on its positive-mode high-resolution electrospray ionization mass spectrum (HRESIMS) at *m/z* 573.19426 (calculated for C~27~H~34~O~12~Na^+^, 573.19425), with 11 indices of hydrogen deficiency (IHDs). The IR spectrum showed the presence of hydroxy (ν~max~ 3408 cm**^--^**^1^), γ-lactone (ν~max~ 1783 cm**^--^**^1^), and ester carbonyl (ν~max~ 1733 cm**^--^**^1^) groups. The ^1^H, ^13^C, and heteronuclear single quantum coherence (HSQC) spectra indicated the presence of seven methyls, two sp^3^ methylenes, six sp^3^ methines, three sp^3^ quaternary carbons, two sp^2^ methines, two quaternary olefinic carbons, and five ester-equivalents ([Table 1](#marinedrugs-18-00383-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00383-t002){ref-type="table"}), accounting for all carbons and 33 of the 34 protons. Two of the sp^3^ quaternary carbons had ^13^C chemical shifts at δ~C~ 80.8 and 94.0, indicative of an oxygen-bearing quaternary carbon and a hemiketal carbon, respectively. A tetracyclic scaffold was deduced by IHDs, as seven of the 11 unsaturation degrees could be assigned to a pair of carbon--carbon double bonds (δ~C~ 138.4, C-5; 128.0, CH-6; 131.1, C-11; 122.0, CH-12) and five esters (δ~C~ 164.6, 169.2, 169.7, 173.2, 174.9).

The ^1^H NMR coupling information in the ^1^H--^1^H correlation spectroscopy (COSY) of **1** enabled the identification of four different spin systems, H-2/H~2~-3, H-6/H-7, H-12/H~2~-13/H-14, and H-17/H~3~-18 ([Figure 2](#marinedrugs-18-00383-f002){ref-type="fig"}), which were assembled with the assistance of a heteronuclear multiple-bond correlation (HMBC) experiment. The ^2^*J*- or ^3^*J*-^1^H--^13^C long-range correlations between H-2, H-3α, H-6/C-4, H-3α/C-2, H-9/C-1, and H-9/C-11 permitted elucidation of the main carbon skeleton of **1**. A vinyl methyl at C-11 was confirmed by an allylic coupling between H-12 (δ~H~ 5.56) and H~3~-20 (δ~H~ 1.96) in the COSY experiment. The ^2^*J*- or ^3^*J*-^1^H--^13^C long-range correlations between H-2, H-3α, H-6/C-4, H-3α/C-2, H-9/C-1, and H-9/C-11 permitted elucidation of the main carbon skeleton of **1**. A vinyl methyl at C-11 was confirmed by an allylic coupling between H-12 (δ~H~ 5.56) and H~3~-20 (δ~H~ 1.96) in the COSY experiment and by the HMBC between H~3~-20/C-11 and C-12. The ring junction Me-15 at C-1 was supported by the HMBC between H~3~-15/C-1, C-2, C-10, C-14, and H-2/C-15. Thus, the methyl-esterified carboxyl group at C-5 was supported by an HMBC between δ~H~ 3.81 (3H, s, --OMe), with δ~C~ 164.6 (C-16). The acetate ester at C-9 was established by a correlation between H-9 (δ~H~ 6.05) and the acetate carbonyl at δ~C~ 169.7 observed in the HMBC spectrum. The C-4 hydroxy group was concluded to be a part of a hemiketal constellation on the basis of a characteristic carbon signal at δ~C~ 94.0 (a quaternary hemiketal carbon, C-4). An oxygenated quaternary carbon signal at δ~C~ 80.8 showed a ^3^*J*-coupling with the methyl protons at δ~H~ 1.46 (H~3~-18). In total, 8 of the 12 oxygen atoms in the molecular formula could be accounted for the presence of a γ-lactone, an ester, a hemiketal, and an α,β-unsaturated methyl esterified carboxyl group. Thus, the remaining four oxygen atoms had to be positioned at C-2 and C-14 as acetoxy groups, respectively, as indicated by their ^1^H and ^13^C NMR chemical shifts (δ~H~ 5.11, 1H, d, *J* = 7.2 Hz; δ~C~ 72.1, CH-2; δ~H~ 5.18, 1H, d, *J* = 4.2 Hz; δ~C~ 71.8, CH-14), although no HMBC correlation was observed from H-2 and H-14 to any acetate carbonyl. These findings, together with the HMBC between H-17/C-19 and H~3~-18/C-17 and C-19, were used to establish the molecular framework of **1**.

The stereochemical evaluation of **1** was approached using a nuclear Overhauser effect spectroscopy (NOESY) experiment ([Figure 2](#marinedrugs-18-00383-f002){ref-type="fig"}) and was found to be compatible with that of **1** offered by computer modeling \[[@B6-marinedrugs-18-00383]\] and that obtained from vicinal proton coupling constant analysis. Proton H-10 exhibited correlations with H-2, H-9, and H~3~-18, while H-14 correlated with H~3~-15, setting the Me-15 at C-1 as *trans* to H-10, as observed in all naturally occurring briarane-type diterpenoids \[[@B7-marinedrugs-18-00383]\]. Due to Me-18 at C-17 being α-oriented in the γ-lactone moiety, H-17 should be positioned on the β face. This proton showed a slight correlation with H-7, indicating that H-7 was β-oriented. H-7 showed a correlation with H-6, and a coupling constant (*J* = 4.8 Hz) was detected between H-7 and H-6, indicating that the dihedral angle between H-6 and H-7 is approximately 60°, and that H-6 is β-oriented. The hydroxy proton at δ~H~ 6.11 (OH-4) displayed a light correlation with H-2, setting the hydroxy group at C-4 in an *S*\*-configuration. The NOESY spectrum also showed correlations of H-6/ H-7 and OH-4/H-2 and with H-12/H~3~-20, revealing the *E*-geometry and *Z*-geometry of C-5/C-6 and C-11/C-12 double bonds, respectively. The remaining stereogenic carbon, C-8, lacked a proton, but there were correlations between H-7/H-17 and H-7/H-9, indicating that C-8 was in an *R*\*-configuration, as evidenced by modeling analysis. Based on the above findings, the relative configurations of stereogenic carbons of **1** were elucidated as 1*R*\*,2*S*\*,4*S*\*,7*S*\*,8*R*\*,9*S*\*,10*S*\*,14*S*\*, and 17*R*\*. As briaranes **1**--**4** were isolated along with the known briaranes excavatolide A and briaexcavatolide F \[[@B8-marinedrugs-18-00383],[@B9-marinedrugs-18-00383]\] from the same target organism, the absolute configurations of these two compounds were determined by single-crystal X-ray diffraction analysis \[[@B10-marinedrugs-18-00383]\]. Therefore, it is reasonable on biogenetic grounds to conclude that briaranes **1**--**4** have the same absolute configuration as those of excavatolide A and briaexcavatolide F. Based on the above findings, the configurations of the stereogenic carbon of **1** were elucidated as 1*R*,2*S*,4*S*,7*S*,8*R*,9*S*,10*S*,14*S*, and 17*R* ([Supplementary Materials, Figures S1--S10](#app1-marinedrugs-18-00383){ref-type="app"}).

Briarane **2** (briarenol R) was isolated as an amorphous powder that showed two sodiated adduct ion peaks in (+)-HRESIMS at *m/z* 519.13912 and 521.13596 (3:1), which accounted for a chlorine atom in the molecular formula, C~24~H~29~^35^ClO~9~ (calculated for C~24~H~29~^35^ClO~9~ + Na, 519.13923) (10 degrees of unsaturation). The IR spectrum of **2** showed α,β-unsaturated ketone, ester carbonyl, γ-lactone, and broad OH stretching at 1682, 1742, 1783, and 3455 cm^--1^, respectively. From the ^13^C and ^1^H NMR ([Table 1](#marinedrugs-18-00383-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00383-t002){ref-type="table"}), HSQC, and HMBC spectra ([Figure 3](#marinedrugs-18-00383-f003){ref-type="fig"}), an α,β-unsaturated ketone was deduced from the signals of three carbons at δ~C~ 201.6 (C-12), 124.4 (CH-13), and 152.5 (CH-14). The presence of an exocyclic olefin was confirmed by the signal of an sp^2^ methylene carbon at δ~C~ 120.3 (CH~2~-16) and further supported by two olefin proton signals at δ~H~ 5.79 (1H, d, *J* = 3.0 Hz, H-16a) and 6.06 (1H, d, *J* = 3.0 Hz, H-16b) in the ^1^H NMR spectrum. In addition, three carbonyl resonances at δ~C~ 173.7 (C-19), 169.6, and 169.3 (2 × ester carbonyls) confirmed the presence of γ-lactone and two ester groups; two acetate methyls (δ~H~ 2.23 and 2.27, both 3H × s; δ~C~ 20.9 and 21.8, CH~3~ × 2) were observed. A disubstituted epoxy group was confirmed from the signals of two oxymethine carbons at δ~C~ 60.2 (CH-3) and 57.4 (CH-4). The chemical shifts of oxymethine protons at δ~H~ 3.48 (1H, dd, *J* = 9.0, 4.2 Hz, H-3) and 3.67 (1H, d, *J* = 4.2 Hz, H-4) further confirmed the presence of this group. Based on the ^13^C NMR data and unsaturated numbers, **2** was established as a tetracyclic briarane. It was observed that the spectroscopic data of **2** resembled those of a known briarane, pachyclavulide D (**5**) ([Figure 1](#marinedrugs-18-00383-f001){ref-type="fig"}), obtained from the soft coral *Pachyclavularia violacea* \[[@B11-marinedrugs-18-00383]\]. Comparison of the proton chemical shifts, coupling patterns, and coupling constants for oxymethine protons H-3 (δ~H~ 3.38, 1H, dd, *J* = 9.0, 4.2 Hz) and H-4 (δ~H~ 3.67, 1H, d, *J* = 4.2 Hz) of **2** with those of **5** (δ~H~ 3.49, 1H, dd, *J* = 8.9, 3.7 Hz, H-3; 3.66, 1H, d, *J* = 3.7 Hz, H-4) \[[@B11-marinedrugs-18-00383]\] indicated the 3,4-epoxide group towards the α-side of the briarane system as that of **5**. Furthermore, the 1D and 2D NMR spectra revealed that the signals corresponding to the 11α-hydroxy group in **5** were replaced by those of a proton in **2**. Therefore, briarenol R (**2**) was assigned as having a structure with the same stereochemistry as **5** because of the stereogenic carbons that **2** has in common with **5**, as confirmed by correlations observed in the NOESY spectrum ([Figure 3](#marinedrugs-18-00383-f003){ref-type="fig"}). Therefore, the configurations of the stereogenic carbons of **2** were elucidated as 1*S*,2*R*,3*R*,4*R*,6*S*, 7*R*,8*R*,9*S*,10*S*,11*R*, and 17*R* ([Supplementary Materials, Figures S11--S20](#app1-marinedrugs-18-00383){ref-type="app"}).

The molecular formula of briarenol S (**3**), containing a chlorine atom, was found to be C~24~H~31~ClO~9~ by (+)-HRESIMS at *m/z* 521.15499 (calculated for C~24~H~31~^35^ClO~9~, 521.15488). The IR spectrum showed absorptions at 3459 cm^--1^ due to hydroxy groups at 1777, 1737, and 1678 cm^--1^, due to γ-lactone, ester carbonyl, and α,β-unsaturated ketonic carbonyl groups, respectively. The ^13^C and ^1^H NMR spectra ([Table 1](#marinedrugs-18-00383-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00383-t002){ref-type="table"}) disclosed the signals due to five methyls, an sp^3^ methylene, eight sp^3^ methines, two sp^3^ quaternary carbons, an sp^2^ methylene, two sp^2^ methines, an sp^2^ quaternary carbon, and four carbonyl carbons. The low-field ester carbonyl carbon (δ~C~ 175.6), coupled with the IR absorption at 1777 cm^--1^, suggested the presence of a γ-lactone moiety in **3**. The high-field ketonic carbonyl carbon at δ~C~ 202.4 suggested that the carbonyl group was conjugated with a carbon--carbon double bond. The ^1^H NMR spectrum ([Table 2](#marinedrugs-18-00383-t002){ref-type="table"}) showed the signals due to two secondary methyls, a tertiary metyl, two acetate methyls, an aliphatic methylene, three aliphatic methines, a methine bearing a chlorine atom, four oxymethines, an exomethylene, and two olefinic methines. These spectroscopic data, coupled with the degrees of unsaturation (IHDs = 9), suggested that compound **3** is a tricyclic diterpenoid with a γ-lactone, an α,β-unsaturated ketone, an exocyclic olefin, and two acetoxy groups. It was found that the spectroscopic data of **3** were similar to those of a known briarane, solenolide E (**6**), isolated from a soft coral identified as *Solenopodium* sp. (= *Briareum* sp.) \[[@B5-marinedrugs-18-00383]\], collected in the Western Caroline Islands of Palau \[[@B12-marinedrugs-18-00383]\], except that the signals corresponding to one of the C-4 methylene protons in **6** were replaced by signals for an acetoxy group in **3**. In the NOESY experiment, H-4 showed a correlation with H-2, revealing that the acetoxy group at C-4 is on the β face in **3**. The HMBC and COSY correlations, as shown in [Figure 4](#marinedrugs-18-00383-f004){ref-type="fig"}, provided the gross structure for **3**. Hence, briarenol S (**3**) was found to be the 4β-acetoxy derivative of **6** and the stereochemistry of the stereogenic carbons in **3** was deduced by NOESY analysis ([Figure 4](#marinedrugs-18-00383-f004){ref-type="fig"}), determined as 1*S*,2*S*,4*R*,6*S*,7*R*, 8*R*,9*S*,10*S*,11*R*, and 17*R* ([Supplementary Materials, Figures S21--S31](#app1-marinedrugs-18-00383){ref-type="app"}).

Our present study has led to the isolation of a new briarane, briarenol T (**4**). Its molecular formula C~24~H~32~O~8~ was deduced from (+)-HRESIMS at *m/z* 471.19879 (calculated for C~24~H~32~O~8~ + Na, 471.19894). The IR spectrum showed absorptions that indicated three different carbonyl types: γ-lactones (ν~max~ 1772 cm^−1^), esters (ν~max~ 1740 cm^--1^), and α,β-unsaturated ketones (ν~max~ 1683 cm^--1^). The latter structural feature was confirmed by the presence of signals at δ~C~ 202.6 (C-12), 154.6 (CH-14), and 124.1 (CH-13) in the ^13^C NMR spectrum ([Table 1](#marinedrugs-18-00383-t001){ref-type="table"}), and the presence of a mutually coupled pair of doublet signals in the ^1^H NMR spectrum at δ~H~ 5.85 (H-13) and 6.39 (H-14) (*J* = 10.2 Hz) corresponding to the α- and β-olefinic protons, respectively ([Table 2](#marinedrugs-18-00383-t002){ref-type="table"}). The spectroscopic data of **4** were similar to those of a known diterpene, cavernulin B (**7**) ([Figure 1](#marinedrugs-18-00383-f001){ref-type="fig"}), isolated from a sea pen, *Cavernularia* sp., collected from the Eastern Coast of Bay of Bengal near Digna, India \[[@B13-marinedrugs-18-00383]\], except that the signals corresponding to the 12-hydroxy group in **7** disappeared and were replaced by a ketone group in **4**, as assessed by comparing the related spectroscopic data of **4** with those of **7**. The locations of functional groups were confirmed by 2D NMR correlations ([Figure 5](#marinedrugs-18-00383-f005){ref-type="fig"}), and hence the structure of briarenol T was assigned as **4**, and the configurations of the stereogenic carbons were elucidated as 1*S*,2*S*,7*S*,8*R*,9*S*,10*S*,11*R*, and 17*R* ([Figure 4](#marinedrugs-18-00383-f004){ref-type="fig"}) ([Supplementary Materials, Figures S32--S41](#app1-marinedrugs-18-00383){ref-type="app"}).

The effects of briaranes **1**--**4** on the release of iNOS and COX-2 from LPS-stimulated RAW 264.7 macrophage cells were assessed ([Table 3](#marinedrugs-18-00383-t003){ref-type="table"}). Briaranes **3** and **4** were found to inhibit the release of iNOS to 78.50 and 79.95%, respectively. It is interesting to note that **2** enhanced the expression of COX-2 to 112.96%, as compared to results of the cells stimulated with LPS only ([Supplementary Materials, Figure S37](#app1-marinedrugs-18-00383){ref-type="app"}).

3. Materials and Methods {#sec3-marinedrugs-18-00383}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-18-00383}
------------------------------------

NMR spectra were recorded on a 600 MHz Jeol ECZ NMR (Jeol, Tokyo, Japan) spectrometer using the residual CHCl~3~ (δ~H~ 7.26 ppm) and CDCl~3~ (δ~C~ 77.1 ppm) signals as internal references for ^1^H and ^13^C NMR, respectively. ESIMS and HRESIMS were obtained from the Bruker mass spectrometer with 7 Tesla magnets (model: SolariX FTMS system, Bremen, Germany). Column chromatography, HPLC, IR spectra, and optical rotation were performed according to our earlier research \[[@B14-marinedrugs-18-00383]\].

3.2. Animal Material {#sec3dot2-marinedrugs-18-00383}
--------------------

Specimens of *B. stechei* used for this study were collected from an 80 ton culturing tank equipped with a flow-through sea water system located in the National Museum of Marine Biology and Aquarium (NMMBA) at April 2016. Identification of the species of this organism was performed by comparison, as described in previous studies \[[@B5-marinedrugs-18-00383],[@B15-marinedrugs-18-00383],[@B16-marinedrugs-18-00383],[@B17-marinedrugs-18-00383]\]. Living reference specimens are being maintained in the authors' marine organisms culturing tanks and a voucher specimen was deposited in the NMMBA (voucher no.: NMMBA-TW-GC-2016-031), Taiwan.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-18-00383}
-----------------------------

Sliced bodies (wet/dry weight = 3980/1860 g) of the specimen were grounded and extracted with a mixture of MeOH and CH~2~Cl~2~ (1:1) to give an extract (104 g). The extract was then applied to a silica gel column chromatograph (Si C.C.) and eluted with gradients of hexane/EtOAc (stepwise from 50:1−1:2) to furnish fractions A−L. Fractions H and I were combined (19.0 g) and separated on Si C.C. using hexane/EtOAc (stepwise from 50:1, pure EtOAc) to obtain fractions H1−H8. Fraction H6 was chromatographed with Si C.C. using hexane/EtOAc/acetone to obtain fractions H6A−H6K. Fraction H6E was separated by Si C.C. using a mixture of CH~2~Cl~2~ and acetone (4:1) to obtain fractions H6E1−H6E6. Fraction H6E2 was repurified by NP-HPLC using a mixture of CH~2~Cl~2~ and acetone (8:1; at a flow rate = 2.0 mL/min) to yield fractions H6E2A−H6E2E. Fraction H6E2C was separated by RP-HPLC using a mixture of MeOH and H~2~O (60:40; at a flow rate = 4.0 mL/min) to obtain **2** (0.6 mg), **4** (0.3 mg), and **1** (0.3 mg), respectively. Fraction H6G was chromatographed on reverse-phase silica gel, using a mixture of acetonitrile and H~2~O (1:1) to obtain fractions H6G1--H6G5. Fraction H6G3 was repurified by NP-HPLC using a mixture of dichloromethane and acetone (5:1) to yield fractions H6G3A−H6G3D. Fraction H6G3B was separated by NP-HPLC using a mixture of dichloromethane and acetone (8:1) to yield fractions H6G3B1−H6G3B5. Fraction H6G3B5 was separated by RP-HPLC with a mixture of MeOH and H~2~O (60:40, at a flow rate of 1.0 mL/min) to afford **3** (0.3 mg).

Briarenol Q (**1**): Amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ +22 (*c* 0.1, CHCl~3~); IR (KBr) ν~max~ 3408, 1783, 1733 cm^−1^; ^13^C (150 MHz, CDCl~3~) and ^1^H (600 MHz, CDCl~3~) NMR data, see [Table 1](#marinedrugs-18-00383-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00383-t002){ref-type="table"}; ESIMS: *m/z* 573 \[M + Na\]^+^; HRESIMS: *m/z* 573.19426 (calculated for C~27~H~34~O~12~ + Na, 573.19425).

Briarenol R (**2**): Amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{22}$ −55 (*c* 0.2, CHCl~3~); IR (KBr) ν~max~ 3455, 1783, 1742, 1682 cm^−1^; ^13^C (150 MHz, CDCl~3~) and ^1^H (600 MHz, CDCl~3~) NMR data, see [Table 1](#marinedrugs-18-00383-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00383-t002){ref-type="table"}; ESIMS: *m/z* 519 \[M + Na\]^+^, 521 \[M + 2 + Na\]^+^; HRESIMS: *m/z* 519.13912 (calculated for C~24~H~29~^35^ClO~9~ + Na, 519.13923).

Briarenol S (**3**): Amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{24}$ +34 (*c* 0.1, CHCl~3~); IR (KBr) ν~max~ 3459, 1777, 1738, 1678 cm^−1^; ^13^C (150 MHz, CDCl~3~) and ^1^H (600 MHz, CDCl~3~) NMR data, see [Table 1](#marinedrugs-18-00383-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00383-t002){ref-type="table"}; ESIMS: *m/z* 521 \[M + Na\]^+^, 523 \[M + 2 + Na\]^+^; HRESIMS: *m/z* 521.15499 (calculated for C~24~H~31~^35^ClO~9~ + Na, 521.15488).

Briarenol T (**4**): Amorphous powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ −30 (*c* 0.1, CHCl~3~); IR (KBr) ν~max~ 3445, 1772, 1740, 1683 cm^−1^; ^13^C (150 MHz, CDCl~3~) and ^1^H (600 MHz, CDCl~3~) NMR data, see [Table 1](#marinedrugs-18-00383-t001){ref-type="table"} and [Table 2](#marinedrugs-18-00383-t002){ref-type="table"}; ESIMS: *m/z* 471 \[M + Na\]^+^; HRESIMS: *m/z* 471.19879 (calculated for C~24~H~32~O~8~ + Na, 471.19894).

3.4. Molecular Mechanics Calculations {#sec3dot4-marinedrugs-18-00383}
-------------------------------------

The MM2 force field \[[@B6-marinedrugs-18-00383]\] in CHEM3D PRO software from CambridgeSoft Corporation (version 15.0, Cambridge, MA, USA) was used to calculate the molecular models.

3.5. In Vitro Anti-inflammatory Assay {#sec3dot5-marinedrugs-18-00383}
-------------------------------------

The anti-inflammatory assay was employed to evaluate the activities of briaranes **1**‒**4** in reducing the release of iNOS and COX-2 from macrophage cells, as the literature reported \[[@B18-marinedrugs-18-00383]\].

4. Conclusions {#sec4-marinedrugs-18-00383}
==============

Four new briaranes, briarenols Q‒T (**1**‒**4**), were identified from a cultured-type octocoral *B. stechei*, which was originally inhabiting and distributed in Taiwanese waters, an area with high biodiversity at the intersection of the Kuroshio current and South China Sea surface current. The structures of compounds **1**‒**4** were elucidated on the basis of spectroscopic analysis and were further confirmed by consideration of biogenetic grounds with modeling compounds that were isolated from the same target cultured octocoral. Briaranes **3** and **4** displayed promising inhibitory effects on the production of iNOS at a concentration of 10 μM. Compound **1** did not exhibit anti-inflammatory activity in this study; more bioactivity screening should be carried out to discover the pharmaceutical potential of the compounds.

Supplementary Materials are available online at <https://www.mdpi.com/1660-3397/18/8/383/s1>. ESIMS, HRESIMS, IR, 1D (^1^H and ^13^C) and 2D (HSQC, HMBC, COSY, and NOESY) NMR spectra of briarenols Q--T (**1**--**4**).
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###### 

The ^13^C NMR (δ~C~ 150 MHz, CDCl~3~) data for briaranes **1**--**4**.

  -----------------------------------------------------------------------
  Position    1               2              3              4
  ----------- --------------- -------------- -------------- -------------
  1           44.3, C ^a^     41.1, C        43.9, C        44.1, C

  2           72.1, CH        76.0, CH       78.1, CH       79.5, CH

  3           41.8, CH~2~     60.2, CH       34.5, CH~2~    31.6, CH~2~

  4           94.0, C         57.4, CH       74.2, CH       28.9, CH~2~

  5           138.4, C        133.6, C       n\. o. ^c^     147.2, C

  6           128.0, CH       60.9, CH       62.3, CH       118.1, CH

  7           70.1, CH        76.3, CH       77.2, CH       77.7, CH

  8           80.8, C         84.2, C        85.0, C        82.2, C

  9           77.2, CH        68.4, CH       74.2, CH       71.3, CH

  10          40.7, CH        39.2, CH       38.8, CH       38.3, CH

  11          131.1, C        44.7, CH       47.3, CH       48.5, CH

  12          122.0, CH       201.6, C       202.4, C       202.6, C

  13          28.4, CH~2~     124.4, CH      124.5, CH      124.1, CH

  14          71.8, CH        152.5, CH      155.1, CH      154.6, CH

  15          13.4, CH~3~     14.6, CH~3~    18.1, CH~3~    15.4, CH~3~

  16          164.6, C        120.3, CH~2~   122.8, CH~2~   28.4, CH~3~

  17          48.0, CH        45.5, CH       45.4, CH       42.6, CH

  18          8.7, CH~3~      6.2, CH~3~     7.7, CH~3~     6.8, CH~3~

  19          174.9, C        173.7, C       175.6, C       175.5, C

  20          24.2, CH~3~     15.6, CH~3~    15.3, CH~3~    15.0, CH~3~

  OAc-2       169.2, C ^b^\   169.6, C\      169.8, C\      168.9, C\
              21.3, CH~3~     20.9, CH~3~    21.0, CH~3~    21.7, CH~3~

  OAc-4                                      169.1, C\      
                                             21.0, CH~3~    

  OAc-9       169.7, C\       169.3, C\                     170.2, C\
              21.0, CH~3~     21.8, CH~3~                   21.1, CH~3~

  OAc-14      173.2, C ^b^\                                 
              21.3, CH~3~                                   

  OCH~3~-16   52.4, CH~3~                                   
  -----------------------------------------------------------------------

^a^ Multiplicity deduced by ^13^C and HSQC spectra; ^b^ data exchangeable; ^c^ n. o. = not obersved.
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###### 

The ^1^H NMR (δ~H~ 600 MHz, CDCl~3~) data (*J* in Hz) for briaranes **1**--**4**.

  Position    1                          2                            3                            4
  ----------- -------------------------- ---------------------------- ---------------------------- ----------------------------
  2           5.11 d (7.2)               4.75 d (9.0)                 4.63 dd (3.6, 3.0)           4.44 dd (6.6, 1.2)
  3α          2.46 d (16.8)                                           1.86 ddd (15.6, 3.6, 3.6)    1.70 m
  β           3.40 dd (16.8, 7.2)        3.48 dd (9.0, 4.2)           3.00 ddd (15.6, 12.0, 3.0)   2.75 m
  4α                                                                  5.81 dd (12.0, 3.6)          2.06 ddd (14.4, 14.4, 4.8)
  β                                      3.67 d (4.2)                                              2.54 m
  6           6.84 d (4.8)               5.39 m                       5.29 br s                    5.44 br d (10.2)
  7           4.44 d (4.8)               5.08 d (3.6)                 5.41 d (3.0)                 5.23 d (10.2)
  9           6.05 s                     5.57 d (8.4)                 3.90 dd (6.0, 6.0)           5.30 d (4.8)
  10          3.10 br s                  2.51 dd (8.4, 4.2)           2.67 br s                    2.69 dd (4.8, 4.2)
  11                                     2.87 qd (7.2, 4.2)           2.45 m                       2.50 qd (7.2, 4.2)
  12          5.56 br s                                                                            
  13α/β       2.02 m; 2.38 br d (18.0)   5.88 dd (10.2, 0.6)          5.89 d (10.2)                5.85 d (10.2)
  14          5.18 d (4.2)               6.37 d (10.2)                6.47 d (10.2)                6.39 d (10.2)
  15          1.04 s                     1.28 s                       1.46 s                       1.23 s
  16a/b                                  5.79 d (3.0); 6.06 d (3.0)   5.72 s; 5.89 s               1.99 d (1.2)
  17          2.79 q (7.2)               2.50 q (7.2)                 3.05 q (7.8)                 2.44 q (7.2)
  18          1.46 d (7.2)               1.25 d (7.2)                 1.19 d (7.8)                 1.21 d (7.2)
  20          1.96 br s                  1.30 d (7.2)                 1.25 d (7.2)                 1.32 d (7.2)
  OH-4        6.11 s                                                                               
  OH-8                                   3.52 s                       3.42 s                       n\. o. ^b^
  OAc-2       2.04 s ^a^                 2.23 s                       2.09 s ^a^                   2.24 s
  OAc-4                                                               2.17 s ^a^                   
  OAc-9       2.03 s                     2.27 s                                                    2.13 s
  OAc-14      2.11 s ^a^                                                                           
  OCH~3~-16   3.81 s                                                                               

^a^ Data exchangeable; ^b^ n. o. = not observed.
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###### 

Western blotting showed that briaranes **3** and **4** suppressed the expression of iNOS. Data were normalized to the cells treated with LPS only, while cells treated with dexamethasone (Dex) (10 μM) were used as a positive control.

  Compound        iNOS              COX-2
  --------------- ----------------- ----------------
  Control         1.28 ± 0.29       0.76 ± 0.13
  LPS             100.00 ± 1.87     100.00 ± 3.26
  **1**           98.27 ± 5.13      94.00 ± 3.47
  **2**           84.53 ± 4.66 \*   112.96 ± 4.54
  **3**           78.50 ± 3.45 \*   97.66 ± 4.60
  **4**           79.95 ± 2.94 \*   104.66 ± 7.86
  Dexamethasone   24.56 ± 1.85 \*   6.56 ± 1.18 \*

Data are presented as the mean ± SEM (*n* = 4); \* significantly different from cells treated with LPS (*p* \< 0.05).

[^1]: These authors contributed equally to this work.
